Immunogenicity 489

summary
Sample ID
None
Response
Negative
Tumor Type
Melanoma
Gene Symbol
ATP5MF-PTCD1
Transcript ID
None
HLA INFO
B*08:01
TCR INFO

No TCR info found!

T cell Tumor cell B*08:01
sequence
Full length protein sequence (749 aa)
MASVV
1
PVKDK
6
KLLEV
11
KLGEL
16
PSWIL
21
MRDFS
26
PSGIF
31
GAFQR
36
GPGGT
41
GKPEM
46
DFVRL
51
ARLFA
56
RARPM
61
GLFIL
66
QHLDP
71
CRARW
76
AGGRE
81
GLMRP
86
MWAPF
91
SSSSS
96
QLPLG
101
QERQE
106
NTGSL
111
GSDPS
116
HSNST
121
ATQEE
126
DEEEE
131
ESFGT
136
LSDKY
141
SSRRL
146
FRKSA
151
AQFHN
156
LRFGE
161
RRDEQ
166
MEPEP
171
KLWRG
176
RRNTP
181
YWYFL
186
QCKHL
191
IKEGK
196
LVEAL
201
DLFER
206
QMLKE
211
ERLQP
216
MESNY
221
TVLIG
226
GCGRV
231
GYLKK
236
AFNLY
241
NQMKK
246
RDLEP
251
SDATY
256
TALFN
261
VCAES
266
PWKDS
271
ALQSA
276
LKLRQ
281
QLQAK
286
NFELN
291
LKTYH
296
ALLKM
301
AAKCA
306
DLRMC
311
LDVFK
316
EIIHK
321
GHVVT
326
EETFS
331
FLLMG
336
CIQDK
341
KTGFR
346
YALQV
351
WRLML
356
SLGLQ
361
PSRDS
366
YNLLL
371
VAARD
376
CGLGD
381
PQVAS
386
ELLLK
391
PREEA
396
TVLQP
401
PVSRQ
406
RPRRT
411
AQAKA
416
GNLMS
421
AMLHV
426
EALER
431
QLFLE
436
PSQAL
441
GPPEP
446
PEARV
451
PGKAQ
456
PEVDT
461
KAEPS
466
HTAAL
471
TAVAL
476
KPPPV
481
ELEVN
486
LLTPG
491
AVPPT
496
VVSFG
501
TVTTP
506
ADRLA
511
LIGGL
516
EGFLS
521
KMAEH
526
RQQPD
531
IRTLT
536
LLAEV
541
VESGS
546
PAESL
551
LLALL
556
DEHQV
561
EADLT
566
FFNTL
571
VRKKS
576
KLGDL
581
EGAKA
586
LLPVL
591
AKRGL
596
VPNLQ
601
TFCNL
606
AIGCH
611
RPKDG
616
LQLLT
621
DMKKS
626
QVTPN
631
THIYS
636
ALINA
641
AIRKL
646
NYTYL
651
ISILK
656
DMKQN
661
RVPVN
666
EVVIR
671
QLEFA
676
AQYPP
681
TFDRY
686
QGKNT
691
YLEKI
696
DGFRA
701
YYKQW
706
LTVMP
711
AEETP
716
HPWQK
721
FRTKP
726
QGDQD
731
TGKEA
736
DDGCA
741
LGGR
746
Mutation Information
DNA mutation:
None
Peptide Range:
57 ~ 80
Mut AA position:
57 (1 in Wild Type peptide)
Alignment
Wild Type:
"------------RLFARARPM---
.||||||||
Mutant:
TGKPEMDFVRLAQLFARARPMGLF"
reference

Nature, 2017

An immunogenic personal neoantigen vaccine for patients with melanoma

Gene Name (from Reference) ATP5J2-PTCD1

clinic trial
Checkpoint Blockade

None

ACT

None

Vaccination

None

Curative Effect

None

experiment
minimal_peptide

None

Antigen Type

None

T-cell Source

PBMCs

APC Type

autologous APCs

Assay

IFNg ELISPOT assay